Dapagliflozin for treating chronic kidney disease

Dapagliflozin (Forxiga) is available on the NHS as a possible treatment for chronic kidney disease (CKD) in adults. You can have dapagliflozin if:

• it is taken alongside standard care including, if you can have them, the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor antagonists, and
• you have an estimated glomerular filtration rate (eGFR) of:
  • 20 ml/min/1.73 m² to less than 45 ml/min/1.73 m², or
  • 45 ml/min/1.73 m² to 90 ml/min/1.73 m², and either:
    • a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or
    • type 2 diabetes.

If you are not eligible for dapagliflozin but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

• How well does it work compared with other treatments?
• What are the risks or side effects? How likely are they?
• How will the treatment affect my day-to-day life?
• What happens if the treatment does not work?
• What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on chronic kidney disease may be a good place to find out more.

These organisations can give you advice and support:

• Kidney Care UK, 0808 801 00 00
• Kidney Research UK, 0300 303 1100

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7089-6